Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Cytogenetic subgroup analysis of the advance trial: A randomized multi-center study of carfilzomib, lenalidomide and dexamethasone (KRd) with or without daratumumab (D) in patients with newly diagnosed multiple myeloma (NDMM)

View Full Paper
Ask AI
Bookmark
Share

Authors

BDBenjamin DiamondDCDavid G. CoffeyKKK Koubek

Discussion

Loading...

Member takes

Overview

Randomized trial improved minimal residual disease rates in newly diagnosed multiple myeloma, suggesting daratumumab adds benefit across cytogenetic subgroups.

Key Points

  • This analysis aimed to evaluate the impact of daratumumab on MRD negativity across cytogenetic subgroups in NDMM.
  • Patients with newly diagnosed multiple myeloma were randomized 1:1 to receive DKRd or KRd.
  • Patients were assessed for minimal residual disease (MRD) after 8 cycles using next-generation sequencing (NGS).
  • Cytogenetics were determined by fluorescence in situ hybridization.
  • MRD-negative patients proceeded to lenalidomide maintenance, while MRD-positive patients were offered autologous stem cell transplant.
  • Patients receiving DKRd had higher MRD negativity rates compared to KRd.
  • For patients with gain(1q), MRD negativity was 65% with DKRd versus 41% with KRd.
  • Patients with t(4;14) had MRD negativity rates of 62% with DKRd compared to 33% with KRd.
  • MRD negativity rates improved with DKRd across various cytogenetic subgroups, indicating a consistent benefit.

Cite This Study

Diamond et al. (2025) studied this question.

synapsesocial.com/papers/69362f6c4fa91c937236e00ehttps://doi.org/10.1182/blood-2025-5763
View Full Paper
Ask AI
Bookmark
Share